EUCTR2005-004290-19-ES进行中（未招募）1 期
Ensayo doble ciego, controlado con placebo, en grupos paralelos, prueba conceptual del ensayo para valorar la tolerabilidad, seguridad y eficacia de rotigotina en spray nasal para el tratamiento agudo del periodo sintomático en pacientes con enfermedad de parkinson idiopática en estado avanzado.
Schwarz Biosciences GmbH0 个研究点目标入组 100 人开始时间: 2006年1月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject is informed and has been given ample time and opportunity to think
- •about his/her participation and has given his/her written informed consent.
- •2. Subject is willing and able to comply with all trial requirements.
- •3. Subject is aged =30 years.
- •4. Subject has idiopathic Parkinson disease, of more than 3 years in duration, as
- •defined by the cardinal sign, bradykinesia, plus the presence of at least 1 of the
- •following: resting tremor, rigidity, impairment of postural reflexes, and without
- •any known or suspected cause of Parkinsonism.
- •5. The investigator must observe the subject in both the on” and off” state and
- •determines that the subject is Hoehn and Yahr stage II -IV in both the on”
- •and off” state.
- •6. Subject has a Mini Mental State Examination (MMSE) score of = 25.
- •7. Subject is expected to be on a stable dose of levodopa, either short-acting or
- •sustained release (in combination with benserazide or carbidopa) for at least 28
- •days prior to baseline (Visit 2) of at least 300mg/day, administered in at least 3
- •8. Subject experiences end-of-dose off” episodes despite attempts to optimize
- •levodopa regimen.
- •9. Subject has a UPDRS Part III in off” state of at least 25 points.
- •10. If the subject is receiving a dopamine agonist, entacapone, an anticholinergic
- •agent (eg, benztropine, trihexyphenidyl, parsitan, procyclidine, biperiden), a
- •monoamine oxidase (MAO) - B inhibitor (eg, selegiline, rasagiline), or a N-methyl-
- •D-aspartate (NMDA) -antagonist (eg, amantadine), he/she is expected to be on
- •a stable dose for at least 28 days prior to baseline (Visit 2).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subject has previously participated in this trial or was assigned to treatment with
- •rotigotine in a previous trial.
- •2. Subject has participated in another trial of an investigational drug (or a medical
- •device) within the last 30 days or is currently participating in another trial of an
- •investigational drug (or a medical device).
- •3. Subject has atypical Parkinson syndrome(s), symptomatic Parkinson syndrome(s)
- •due to drugs (eg metoclopramide, flunarizine), metabolic neurogenetic disorders
- •(eg, Wilson disease), encephalitis, cerebrovascular disease or neurodegenerative
- •disease (eg progressive supranuclear palsy).
- •4. Subject has a history of pallidotomy, thalamotomy, deep brain stimulation or fetal
- •tissue transplant.
- •5. Subject has dementia, active hallucinations or active or treated psychosis. If
- •subjects has hallucinations, he/she may participate if hallucinations are treated,
- •and no symptoms occurred during the last 28 days.
- •6. Subject is receiving therapy with any of the following drugs currently or has done
- •so within 3 months prior to the hospital admission visit (Visit 2): MAO-A inhibitors
- •(pargyline, phenelzine and tranylcypromine), tolcapone, budipine, reserpine or
- •alpha-methyldopa.
- •7. Subject is currently receiving CNS active therapy (eg, sedatives, hypnotics, anti-
- •depressants, anxiolytics, atypical neuroleptics), unless the dose has been stable
- •for at least 28 days prior to Visit 2 and is likely to remain stable until end of Visit 3.
- •8. Subject has a current diagnosis of epilepsy, a history of seizures as an adult, a
- •history of stroke or had a TIA within 1 year prior to Visit 1.
- •9. Subject has clinically relevant hepatic dysfunction (as defined as a total bilirubin
- •> 2.0mg/dL or ALT and/or AST greater than 2 times the upper limit of the
- •reference range at Visit 1).
- •10. Subject has clinically relevant renal dysfunction (serum creatinine > 2.0mg/dL
- •[>178µmol/L] at Visit 1).
- •11. Subject has clinically relevant cardiac dysfunction (any cardiac disorder which in
- •the opinion of the investigator would put the subject at risk of clinically relevant
- •arrhythmia) and/or myocardial infarction within 1 year prior to Visit 1.
- •12. Subject has a QTc interval of = 500ms at Visit 1 (the Bazett's correction must be
- •used for the correction of the QT interval).
- •13. Subject has symptoms of rhinitis or local disease or irritation of the nasal mucosa
- •at Visit 2 or Visit 3.
- •14. Subject has had intra-nasal treatment within 14 days prior to Visit 3.
- •15. Subject has a history of symptomatic orthostatic hypotension, or systolic blood
- •pressure less than 105mmHg at trial entry.
- •16. Subject has a history of chronic alcohol or drug abuse within the last 6 months.
- •17. Subject has a known or suspected hypersensitivity to any component of the
- •investigational product or other nasal spray products.
- •18. Subject is pregnant or nursing, or is of child bearing potential but (i) not
- •surgically sterile or (ii) not using adequate birth control methods (including a
- •highly effective method of birth control and at least 1 barrier method) or (iii) not
- •sexually abstinent or (iv) subject is not at least 2 years post-menopausal
- •19. Subject has any medical condition, psychiatric condition or laboratory abnormality
- •that, in the opinion of the investigator, could jeopardize or would compromise
研究者
相似试验
进行中（未招募）
1 期
Ensayo en doble ciego y controlado con placebo, de 12 semanas de duración, de LY2428757 en pacientes con diabetes mellitus de tipo 2.A 12-Week, Double-Blind, Placebo-Controlled Trial of LY2428757 in Patients with Type 2 Diabetes MellitusEUCTR2008-004207-63-ESEli Lilly and Company, Indianapolis300
进行中（未招募）
1 期
Ensayo en doble ciego, controlado con placebo, intrapaciente, para evaluar la eficacia de Juvista (avotermina) junto con cirugía correctora de la cicatriz para la mejoría de cicatrices deformantes.A double blind, within patient, placebo controlled trial to assess the efficacy of Juvista (avotermin) in conjunction with scar revision surgery for the improvement of disfiguring scars. - Juvista in scar revision surgery of disfiguring scarsEUCTR2008-002124-28-ESRenovo Ltd350
进行中（未招募）
不适用
Estudio doble ciego, controlado con placebo sobre la eficacia y tolerancia de V0251 1g, 2g y 4g en neuritis vestibularA double-blind placebo controlled study of 1g, 2g and 4g V0251 efficacy and tolerance in vestibular neuritis.EUCTR2007-005054-23-ESPIERRE FABRE MEDICAMENT - IRPF120
进行中（未招募）
不适用
Estudio doble ciego, controlado con placebo, con aumento gradual de dosis, en grupos paralelos para evaluar la eficacia y la seguridad de E2007 (perampanel) administrado como terapia adyuvante en pacientes con crisis parciales refractariasA Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial SeizureEUCTR2007-006169-33-ESEisai Ltd816
进行中（未招募）
不适用
Studio in doppio cieco controllato con placebo, randomizzato, a gruppi paralleli di fase III per la valutazione dellefficacia e della sicurezza dellestratto ALK- Tablets di Phleum pratense in soggetti con rinocongiuntivite stagionale causata da polline di graminacee.allergic-respiratory deseasesMedDRA version: 14.1Level: SOCClassification code 10038738Term: Respiratory, thoracic and mediastinal disordersSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2004-000083-27-ITALK-ABELLO'600